secwatch.observer — SEC 8-K summary
======================================

Issuer:     ASSEMBLY BIOSCIENCES, INC. (ASMB)
CIK:        0001426800
Form:       8-K
Filed at:   2026-08-13T20:11:18+00:00
Accession:  0001193125-26-349198
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Assembly Bio Q2 net loss narrows to $3.9M; cash $320M, pipeline advances
------------------------------------------------------------------------

- Q2 2026 net loss $3.9M ($0.20/share) vs $10.2M ($1.33) in Q2 2025; revenue from Gilead $13.4M incl. $5.1M catch-up.
- Cash $320.4M at June 30, up from $226.6M; $115M gross financing completed; runway into 2029 incl. $75M Gilead fee due Q4 2026.
- ABI-6250 expanded into cholestatic liver diseases (PBC, PSC); Phase 2 study expected Q1 2027.
- GS-1179 selected for HSV HPI program; Phase 2 initiation expected by year-end 2026; opt-in decision on 40% U.S. cost-profit share by year-end.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1426800/000119312526349198/0001193125-26-349198-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1426800/000119312526349198/asmb-20260813.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-349198

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer